BFS
HUMA icon

Beacon Financial Strategies’s Humacyte HUMA Stock Holding History

Beacon Financial Strategies’s Portfolio HUMA Stock Details HUMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$664 Hold
850
– – ﹤0.01% 205
2026
Q1 		$516 Hold
850
– – ﹤0.01% 175
2025
Q4 		$817 Buy
+850
New +$1.2K ﹤0.01% 178

Other funds holding HUMA

AP
Antipodes Partners Royal Exchange, Australia $5.46B AUM 26.64% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Beacon Financial Strategies's HUMA Position: Q2 2026 in Review

Beacon Financial Strategies held its Humacyte (HUMA) position steady in Q2 2026 at 850 shares worth $664. The position accounts for ﹤0.01% of the portfolio, ranked #205.

Beacon Financial Strategies first reported a position in HUMA in Q4 2025 and has held it in 3 quarters since. The position peaked at $817 in Q4 2025. 161 funds tracked by Wall St. Rank hold HUMA as of Q2 2026.

  • Beacon Financial Strategies held 850 shares of Humacyte worth $664 as of Q2 2026.
  • Beacon Financial Strategies left its Humacyte share count unchanged in Q2 2026.
  • Humacyte made up ﹤0.01% of Beacon Financial Strategies's portfolio in Q2 2026, its #205 holding.
  • Beacon Financial Strategies first reported a position in Humacyte in Q4 2025 and has held it in 3 quarters since.
  • Beacon Financial Strategies's Humacyte position peaked at $817 in Q4 2025.
  • 161 funds tracked by Wall St. Rank held Humacyte as of Q2 2026.

Based on Beacon Financial Strategies's 13F filing for Q2 2026, filed 8 Jul 2026.